-
SpeichernDas Eingabefeld wird
gespeichert wenn Sie das Feld
verlassen oder hier klicken.Börse Tradegate System der Deutsche Börse AG (60%)Symbol MYD-
Myriad GeneticsBörse Xetra FrankfurtSymbol MYD
-
Myriad GeneticsBörse Börse FrankfurtSymbol MYD
-
Myriad GeneticsBörse Börse BerlinSymbol MYD
-
Myriad GeneticsBörse Börse StuttgartSymbol MYD
-
MYRIAD GENETICS INCBörse Quotrix System der Börse DüsseldorfSymbol MYD
-
MYRIAD GENETICS INCBörse Gettex System der Börse MünchenSymbol MYD
-
MYRIAD GENETICS INCBörse Börse DüsseldorfSymbol MYD
-
MYRIAD GENETICS INCBörse Tradegate System der Deutsche Börse AG (60%)Symbol MYD
-
MYRIAD GENETICS INCBörse Börse HamburgSymbol MYD
-
Myriad GeneticsBörse NasdaqISIN US62855J1043 WKN: 897518Symbol MYGN
-
ISIN US62855J1043 WKN: 897518Symbol MYGN
-
Symbol MYD
-
USD
-
Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:
2.066.032.256 oder 2.196.000.000
Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:
2.700 oder 2.600 Mitarbeiter
Entdecke die 6 ETFs in denen Myriad Genetics, Inc am höchsten gewichtet ist Insgesamt in 9 ETFs enthalten
Dir gefallen die Informationen zu Myriad Genetics?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne ein kostenloses und unverbindliches Depot bei BUX Zero mit der Möglichkeit kostenlos US-Aktien und für einen Euro viele weitere Aktien aus Deutschland, Belgien, Niederlande, sterreich oder UK zu kaufen. Wenn du das über meinen Link machst, bekommen wir beide eine gratis Aktie geschenkt:
Dir gefallen die Informationen zu Myriad Genetics?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein mindestens 3 Jahre lang kostenloses Depot bei der comdirect. Wenn du das über diesen Link machst unterstützt du auch meine Tochter Zoe, da es Ihr Juniordepot ist. Sie erhält 20 und bei einem aktiven ETF- oder Aktien-Sparplan bleibt dein Depot auch danach kostenfrei:
Dir gefallen die Informationen zu Myriad Genetics?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein kostenloses und unverbindliches Depot bei der ING Diba. Ich erhalte 20 wenn du daraufhin dann zum Beispiel einen Aktien-Sparplan anlegst oder etwas kaufst:
Dir gefallen die Informationen zu Myriad Genetics?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein kostenloses und unverbindliches Depot bei Trade Republic mit der Möglichkeit kostenlos Aktien zu besparen. Wenn du das über meinen Link machst, bekommst du und ich bei deinem ersten Wertpapierkauf 15 von Trade Republic geschenkt:
30 News & Informationen zur Myriad Genetics Aktie
Global Companion Diagnostics Market Report 2021-2027: Broader Scope and Applications Rev Up Growth Opportunities
/PRNewswire/ — The
Global Companion Diagnostics Market Report 2021-2027: Broader Scope And Applications Rev Up Growth Opportunities
DUBLIN, Aug. 24, 2021 /PRNewswire/ — The
Global Direct-to-Consumer Genetic Testing Market 2021: Massive Scope For Adoption Of Genomic-Based Medicine In Emerging Nations – Forecast To 2031
DUBLIN, Aug. 20, 2021 /PRNewswire/ — The “Global Direct-to-Consumer Genetic Testing Market: Focus on Direct-to-Consumer Genetic Testing Market by Product
Tryp Therapeutics Appoints Dennis Langer, M.D., J.D. as Senior Advisor
Tryp Therapeutics , a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today the appointment of Dennis Langer, M.D., J.D., as… | August 18, 2021
Cancer Diagnostics Market Size to Reach USD 268.10 Billion in 2028: CAGR of 6.3% | Reports and Data
NEW YORK, Aug. 16, 2021 /PRNewswire/ — The global cancer diagnostics market size is expected to reach USD 268.10 Billion in 2028 and register a C…
Global Direct-to-Consumer Genetic Testing Market To Reach $6.60 Billion By 2031, Says BIS Research Study
FREMONT, Calif., Aug. 12, 2021 /PRNewswire/ — The premium market intelligence report published by BIS Research on the title Global Direct-to-Consumer Genetic
Myriad Genetics Inc (MYGN) CFO Richard Bryan Riggsbee Sold $526,503 of Shares
GuruFocus Article or News written by insider and the topic is about:
Myriad Genetics (MYGN) Beats Q2 Earnings and Revenue Estimates
Myriad (MYGN) delivered earnings and revenue surprises of 271.43% and 13.60%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Scheduled For August 3, 2021
Companies Reporting Before The Bell
• Myriad Genetics (NASDAQ:MYGN) is likely to report earnings for its fourth quarter.
• Stellantis …
Medpace : Announces Senior Leadership Changes Appointment of Jesse Geiger as President and Kevin Brady as Chief Financial Officer (Form 8-K)
Medpace Holdings, Inc. Announces Senior Leadership Changes
Appointment of Jesse Geiger as President and Kevin Brady as Chief Financial Officer
… | July 26, 2021
Medpace Holdings, Inc. Announces Senior Leadership Changes
Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced the appointment of Jesse Geiger as president and Kevin Brady as chief financial officer,
Washington Federal Inc. (WAFD): Are Hedge Funds Right About This Stock?
Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge…
Here is What Hedge Funds Think About Patria Investments Limited (PAX)
In this article we will check out the progression of hedge fund sentiment towards Patria Investments Limited (NASDAQ:PAX) and determine whether it is…
The Worldwide Precision Medicine Industry is Expected to Reach $738.8 Billion by 2030
DUBLIN, July 7, 2021 /PRNewswire/ — The 'Precision Medicine Market Research Report: By Type (Therapeutics, Diagnostics, Personalized Medical Care…
Global Genetic Testing Market (2020 to 2026) – Featuring Abbott Laboratories, 23andMe & Cepheid Among Others
/PRNewswire/ — The
Global Genetic Testing Market (2020 To 2026) – Featuring Abbott Laboratories, 23andMe & Cepheid Among Others
DUBLIN, July 2, 2021 /PRNewswire/ — The
Myriad Genetics (MYGN) Divests Myriad RBM to Focus on Core Units
Myriad Genetics' (MYGN) new divesture will enable company to accelerate the execution of transformation plan and drive growth.
Myriad Genetics Completes Sale of Myriad RBM to IQVIA’s Q2 Solutions
SALT LAKE CITY, July 01, 2021 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today…
Direct-To-Consumer Genetic Testing Market to grow by USD 1.39 billion during 2021-2025
NEW YORK, June 24, 2021 /PRNewswire/ — The direct-to-consumer genetic testing market is poised to grow by USD 1.39 billion during 2021-2025, prog…
Direct-To-Consumer Genetic Testing Market to grow by USD 1.39 billion during 2021-2025|Technavio
/PRNewswire/ — The direct-to-consumer genetic testing market is poised to grow by USD 1.39 billion during 2021-2025, progressing at a CAGR of over 16% during…
Direct-To-Consumer Genetic Testing Market to grow by USD 1.39 billion during 2021-2025|Technavio
/PRNewswire/ — The direct-to-consumer genetic testing market is poised to grow by USD 1.39 billion during 2021-2025, progressing at a CAGR of over 16% during…
Direct-To-Consumer Genetic Testing Market to grow by USD 1.39 billion during 2021-2025|Technavio
/PRNewswire/ — The direct-to-consumer genetic testing market is poised to grow by USD 1.39 billion during 2021-2025, progressing at a CAGR of over 16% during…
Direct-To-Consumer Genetic Testing Market To Grow By USD 1.39 Billion During 2021-2025|Technavio
NEW YORK, June 24, 2021 /PRNewswire/ — The direct-to-consumer genetic testing market is poised to grow by USD 1.39 billion during 2021-2025, progressing at a
Inari Medical Appoints Outset Medical Executive Rebecca Chambers to Board of Directors
IRVINE, Calif., June 22, 2021 (GLOBE NEWSWIRE) — Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company focused on developing products to…
Myriad Genetics (MYGN), Illumina Partner to Enhance Oncology Arm
Myriad Genetics (MYGN) partners with Illumina to expand the access as well as extend the reach of myChoice CDx through its services offering in the international market.
Myriad Genetics Receives First Reimbursement Decision for myChoice® Diagnostic System in Japan, Enabling Women with Ovarian Cancer to Benefit from Treatment with Zejula®, Business News
Myriad Genetics Receives First Reimbursement Decision for myChoice® Diagnostic System in Japan, Enabling Women with Ovarian Cancer to Benefit from Treatment with Zejula®
GlobeNewswire
January 08, 2021
SALT LAKE CITY, Jan. 08, 2021 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today that…
Stocks making the biggest moves in the premarket: Tesla, Bank of America, solar companies & more
The stocks making the biggest moves in premarket trading include Tesla, Bank of America, solar companies, and more.
The Daily Biotech Pulse: Aerpio Reviews Strategic Options, Hologic Goes Shopping
Here’s a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Jan. 5) Curis, …
Stocks making the biggest moves after the bell: Cal-Maine Foods, Myriad Genetics & more
These are the stocks posting the largest moves after hours on Tuesday.
Global Oncology Precision Medicine Market (2020 to 2030) – Analysis and Forecast
Dublin, Jan. 05, 2021 (GLOBE NEWSWIRE) — The “Global Oncology Precision Medicine Market: Focus on Application Area, Ecosystem Type, Country Data (15 …